Anaplastic Large Cell Lymphoma (DBCOND0028602)

Identifiers

Synonyms
ALCL / Anaplastic large cell lymphoma / Lymphoma, Large-Cell, Anaplastic / Anaplastic large-cell lymphoma / Anaplastic large cell lymphoma, ALK-positive / Large cell anaplastic lymphoma T cell and Null cell type (disorder) / Anaplastic large cell lymphoma, T cell and Null cell type (morphologic abnormality)

Associated Data

Indicated Drugs and Targets
Not Available
Clinical Trials
IdentifierTitleDrug(s)PurposePhaseStatus
NCT06254495
A Safety Study of SGN-35C in Adults With Advanced CancersNo drug interventionstreatment1recruiting
NCT03493451
Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasmstreatment2completed
NCT05377827
Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignanciestreatment1active_not_recruiting
NCT06120504
A Safety Study of SGN-35T in Adults With Advanced CancersNo drug interventionstreatment1recruiting
NCT01748721
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphomatreatment1completed
NCT00649584
A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignanciestreatment1terminated
NCT04195633
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignanciestreatment2recruiting
NCT01116154
Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphomatreatment1terminated
NCT00006251
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancertreatment1 / 2completed
NCT03397953
Vinorelbine for Recurrent ACLCtreatment2completed
NCT00890747
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapytreatment1completed
NCT00293345
3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphomatreatment1completed
NCT01258998
Study of Akt Inhibitor MK2206 in Patients With Relapsed LymphomaNo drug interventionstreatment2completed
NCT00608361
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgerytreatment1completed
NCT01129193
AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphomatreatment1completed
NCT01177371
High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphomatreatment2completed
NCT06494371
A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell LymphomaNo drug interventionstreatment1recruiting
NCT01254578
Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancerstreatment1completed
NCT00082888
Tipifarnib in Treating Patients With Relapsed or Refractory Lymphomatreatment2completed
NCT00117988
17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphomatreatment2completed
NCT00354107
Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphomatreatment1 / 2terminated
NCT01567709
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphomatreatment1completed
NCT00354185
PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomatreatment1terminated
NCT01026415
Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)treatment1completed
NCT00025415
Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunctiontreatment1completed
NCT00131937
Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphomatreatment2completed
NCT00001337
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphomatreatment2completed
NCT01805037
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomastreatment1 / 2terminated
NCT01777152
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomastreatment3completed
NCT00118352
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancertreatment2completed
NCT00003970
Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphomatreatment1completed
NCT00073918
Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphomatreatment2completed
NCT00058019
Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphomatreatment2completed
NCT04526834
Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin LymphomaNo drug interventionstreatment1active_not_recruiting
NCT01839916
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignanciestreatment2completed
NCT02232516
Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphomatreatment2active_not_recruiting
NCT00078858
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplanttreatment1 / 2completed
NCT00014235
Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic MalignanciestreatmentNot Availablecompleted
NCT01686165
Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHLtreatment2completed
NCT01158274
RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumorstreatment1completed
NCT03590574
Phase I/II Study Evaluating AUTO4 in Patients With TRBC1 Positive T Cell LymphomaNo drug interventionstreatment1 / 2recruiting
NCT01336920
Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphomatreatment1completed
NCT00199082
Newly Diagnosed Mature B-ALL, Burkitt's Lymphoma and Other High-grade Lymphoma in Adultstreatment4completed
NCT01657331
Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL)treatment1 / 2completed
NCT01529827
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignanciestreatment2completed
NCT00098891
MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomastreatment1completed
NCT00704691
Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomastreatment0terminated
NCT03205891
Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomastreatment1withdrawn
NCT01199562
Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell TransplantNot AvailableNot Availablecompleted
NCT01309789
A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasmstreatment1completed
NCT02568267
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)treatment2active_not_recruiting
NCT00049504
Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancertreatment2completed
NCT00697346
Study of MLN8237 in Participants With Advanced Hematological Malignanciestreatment1completed
NCT00040846
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignanciestreatment2completed
NCT01466881
Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphomatreatment2completed
NCT03947255
A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphomatreatment2terminated
NCT01196208
A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001Not AvailableNot Availableno_longer_available
NCT01678443
Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignanciestreatment1terminated
NCT01408043
Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin LymphomatreatmentNot Availableterminated
NCT01950364
A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphomatreatment1completed
NCT01075321
Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphomatreatment1 / 2completed
NCT01326702
Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumorstreatment1 / 2completed
NCT01336933
Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphomatreatment2completed
NCT01026233
Cardiac Safety Study of Brentuximab Vedotin (SGN-35)treatment1completed
NCT00918333
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphomatreatment1 / 2completed
NCT01793233
Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed LymphomasNo drug interventionsNot AvailableNot Availablecompleted
NCT05208853
An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory LymphomaNo drug interventionstreatment0unknown_status
NCT01959477
Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplanttreatment0completed
NCT00866047
A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphomatreatment2completed
NCT01261247
Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphomatreatment2completed
NCT05907447
A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological TypesNo drug interventionsNot AvailableNot Availablenot_yet_recruiting
NCT00606645
Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphomatreatment1completed
NCT03598998
Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomastreatment1 / 2active_not_recruiting
NCT00343798
A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignanciestreatment1completed
NCT00096005
Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomastreatment1terminated
NCT01449461
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)treatment1 / 2completed
NCT02465528
Ceritinib Rare Indications Study in ALK+ Tumorstreatment2terminated
NCT00310128
Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphomatreatment2withdrawn
NCT03443128
Vinorelbine for Recurrent ALCL-2017treatment2recruiting
NCT01769911
Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin LymphomatreatmentNot Availablewithdrawn
NCT00089011
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancertreatment2completed
NCT00499811
Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunctiontreatment1completed
NCT00112593
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without CancertreatmentNot Availablecompleted
NCT00089271
17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomastreatment1completed
NCT00856388
Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure DisorderstreatmentNot Availablecompleted
NCT00769288
FAU in Treating Patients With Advanced Solid Tumors or LymphomaNo drug interventionstreatment1completed
NCT01787409
Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D InsufficiencyNo drug interventionstreatmentNot Availablerecruiting
NCT00947856
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Studytreatment2completed
NCT00348985
PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomastreatment1completed
NCT04644315
A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumorstreatment2terminated
NCT02652715
Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin LymphomaNo drug interventionsbasic_scienceNot Availablecompleted
NCT01588015
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell TransplantNo drug interventionssupportive_care1completed
NCT05770037
DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Teenage/Young Adults (TYA) and Paediatric Patients With ALK Positive Cancerstreatment2 / 3recruiting
NCT03049449
T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomastreatment1completed
NCT00601718
Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphomatreatment1 / 2completed
NCT00801918
Denileukine Diftitox for Relapsed ALCLtreatment2withdrawn
NCT01658319
Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignanciestreatment1completed
NCT00004241
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcomatreatment1completed
NCT00003196
Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple MyelomatreatmentNot Availablecompleted
NCT03905135
Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignanciestreatment1completed
NCT00720135
Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphomatreatment1completed
NCT01110135
Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myelomatreatment2completed
NCT06508463
Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphomatreatment1recruiting
NCT03942263
A Study to Describe Treatment Patterns and Disease Control in Participants With cHL and sALCL in Routine Clinical Practice in the Russian FederationNo drug interventionsNot AvailableNot Availablecompleted
NCT01769222
Ipilimumab and Local Radiation for Selected Solid Tumorstreatment1terminated
NCT01273766
Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignanciessupportive_care2completed
NCT03383965
CD30 Targeted CAR-T in Treating CD30-Expressing LymphomasNo drug interventionstreatment1recruiting
NCT00365274
SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphomatreatment2terminated
NCT00278382
Sorafenib in Treating Patients With Recurrent Non-Hodgkin's Lymphomatreatment2completed
NCT01943682
Safety Study of CPX-351 in Children With Relapsed Leukemia or LymphomaNo drug interventionstreatment1completed
NCT00458731
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytomatreatment1completed
NCT04008394
Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte MalignanciesNo drug interventionstreatment1unknown_status
NCT00016094
S0108 Bevacizumab in Treating Patients With Non-Hodgkin's Lymphomatreatment2completed
NCT00005080
506U78 in Treating Patients With Lymphomatreatment2completed
NCT01129180
Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphomatreatment1completed
NCT03534180
Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphomatreatment2completed
NCT00644189
Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphomatreatment1 / 2completed
NCT05106192
Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System.supportive_careNot Availablenot_yet_recruiting
NCT02168140
CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphomatreatment1completed
NCT00103272
17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancertreatment1terminated
NCT00430846
Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignanciestreatment1completed
NCT01427881
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignanciestreatment2completed
NCT01419795
Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplanttreatment2terminated
NCT00072514
Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignanciestreatment2completed
NCT02939014
Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)treatment2completed
NCT01652014
Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignanciestreatment2withdrawn
NCT00079755
Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphomatreatment2completed
NCT00077155
Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphomatreatment1completed
NCT05290155
Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell MalignanciesNo drug interventionstreatment1recruiting
NCT00112723
Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myelomatreatment1 / 2terminated
NCT05160922
Crizotinib Continuation Clinical Studytreatment4active_not_recruiting
NCT02902874
Study of the Biological Mechanisms Associated With the Immunogenicity in Anaplastic Large Cell Lymphoma ( ALCL ) ALK +No drug interventionsbasic_scienceNot Availablecompleted
NCT04021082
CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)treatment2 / 3withdrawn